Premium
Suspected malignant hyperthermia in a child with laminin α 2 (merosin) deficiency in the absence of a triggering agent
Author(s) -
SHUKRY MOHANAD,
GURULI ZURAB V,
RAMADHYANI USHA
Publication year - 2006
Publication title -
pediatric anesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.704
H-Index - 82
eISSN - 1460-9592
pISSN - 1155-5645
DOI - 10.1111/j.1460-9592.2005.01742.x
Subject(s) - medicine , dantrolene , malignant hyperthermia , laminin , grading (engineering) , surgery , anesthesia , extracellular matrix , biology , microbiology and biotechnology , civil engineering , engineering , calcium
Summary Malignant hyperthermia (MH) is an inherited disorder of the skeletal muscles that can be triggered by many anesthetic agents. MH has different presentations and manifestations that makes it difficult to diagnose. Patients with laminin α 2 deficiency have never been reported to be susceptible to MH. We present a suspected MH episode in the absence of classic triggering agents in a 7‐year‐old boy with laminin α 2 (merosin) deficiency and congenital muscular dystrophy. The episode was diagnosed using the MH clinical grading scale and responded well to prompt management with dantrolene. We conclude that patients with laminin α 2 deficiency may be susceptible to MH, and early suspicion and rapid treatment is vital in the management of MH. Anesthesiologists should be prepared to treat MH in susceptible patients even in the absence of a classical triggering agent.